PREVEnt Trial: Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome
The Ehlers-Danlos Society is delighted to be supporting Aytu BioPharma, Inc. who will be sponsoring an upcoming clinical trial to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with:
- Vascular Ehlers-Danlos syndrome (vEDS)
- Confirmed COL3A1 gene mutation
The trial will study the investigational oral compound, enzastaurin, for its inhibition of the protein kinase C (PKC) pathway. The PKC pathway has been implicated in the pathogenesis of vEDS in mouse models. Enzastaurin has been previously studied in over 40 human trials including a range of cancers. The objective of the trial is to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with vascular Ehlers-Danlos syndrome (VEDS) confirmed with COL3A1 gene mutations, compared to placebo.
To register your interest to take part in this trial, click the button below and complete the form.